ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2439

Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
Abstract Number: 2440

Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis
Abstract Number: 2441

Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis
Abstract Number: 2442

Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Abstract Number: 2443

Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Abstract Number: 2444

Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis
Abstract Number: 2445

Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Abstract Number: 2446

Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus
Abstract Number: 2447

Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Abstract Number: 2448

UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes
Abstract Number: 2449

Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 2450

Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis
Abstract Number: 2451

TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank
Abstract Number: 2452

Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Abstract Number: 2453

Development of a Hydroxychloroquine Retinopathy Prediction Score

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].